Core Scientific (CORZ) Asset Writedowns and Impairment (2022 - 2026)

Core Scientific has disclosed Asset Writedowns and Impairment across 4 years of filings, most recently posting $19.5 million for Q2 2026.

• In Q2 2026, Asset Writedowns and Impairment changed N/A year-over-year to $19.5 million; the TTM figure through Jun 2026 stood at $297.4 million (up 1059.93% YoY), while the FY2025 annual figure was $11.4 million, down 90.72% from the prior year.
• Asset Writedowns and Impairment came in at $19.5 million for Q2 2026 at Core Scientific, down from $266.5 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $790.8 million in Q2 2022 to a low of -$784.9 million in Q3 2022.
• Average Asset Writedowns and Impairment over 4 years is $53.7 million, with a median of $22.6 million recorded in 2024.
• The largest YoY upside for Asset Writedowns and Impairment was 55.54% in 2025 against a maximum downside of 55.54% in 2025.
• Over 4 years, Asset Writedowns and Impairment stood at $3.1 million in 2022, then surged by 737.6% to $25.6 million in 2024, then slumped by 55.54% to $11.4 million in 2025, then surged by 71.01% to $19.5 million in 2026.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $19.5 million in Q2 2026, $266.5 million in Q1 2026, and $11.4 million in Q4 2025.